Tricida, Inc. (TCDA): Price and Financial Metrics
GET POWR RATINGS... FREE!
TCDA Stock Price Chart Interactive Chart >
TCDA Price/Volume Stats
| Current price | $4.91 | 52-week high | $28.18 |
| Prev. close | $4.92 | 52-week low | $3.74 |
| Day low | $4.88 | Volume | 139,300 |
| Day high | $5.03 | Avg. volume | 564,318 |
| 50-day MA | $4.76 | Dividend yield | N/A |
| 200-day MA | $6.89 | Market Cap | 246.84M |
Tricida, Inc. (TCDA) Company Bio
Tricida, Inc., a late-stage pharmaceutical company, focuses on developing therapeutics to address renal, metabolic, and cardiovascular disease. Its lead product candidate, TRC101, a non-absorbed orally-administered polymer drug that is in Phase III clinical trials used to treat metabolic acidosis in patients with chronic kidney disease. The company was founded in 2013 and is based in South San Francisco, California.
Latest TCDA News From Around the Web
Below are the latest news stories about Tricida Inc that investors may wish to consider to help them evaluate TCDA as an investment opportunity.
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Zoom, Capital One, and Tricida on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmNEW YORK, June 03, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Zoom Video Communications, Inc. (NASDAQ: ZM), Capital One (NYSE: COF), and Tricida, Inc. (NASDAQ: TCDA) on behalf of long-term stockholders. More information about each potential case can be found at the link provided. Zoom Video Communications, Inc. (NASDAQ: ZM) Bragar Eagel & Squire is investigating certain officers and |
Shareholder Alert: Robbins LLP is Investigating Tricida, Inc. (TCDA) for ShareholdersShareholder rights law firm Robbins LLP is investigating Tricida, Inc. (NASDAQ: TCDA) to determine whether certain Tricida officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company. Tricida is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of non-absorbed therapies. Its lead drug candidate veverimer (TRC101) is intended to slow the progression of chronic kidney disease ("CKD") th |
Tricida to Present at the Goldman Sachs 42nd Annual Global Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 12:50 pm PT / 3:50 pm ET. Gerrit Klaerner, Tricida’s Founder, President and Chief Executive Officer, will provide a company overview, business update and progress on the company’s key initiatives. A live webcast of the presentation will be accessible on the Tricida website at IR |
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Uniti Group, Surgalign Holdings, Tyson Foods, and Tricida on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmNEW YORK, April 09, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Uniti Group, Inc. (NASDAQ: UNIT), Surgalign Holdings, Inc. (f/k/a RTI Surgical Holdings, Inc.) (Nasdaq: SRGA), Tyson Foods (NYSE: TSN), and Tricida, Inc. (NASDAQ: TCDA) on behalf of long-term stockholders. More information about each potential case can be found at the link provided. Uniti Group, Inc. (NASDAQ: UNIT) Bragar Eagel & Squire is is investigating certain officers and directors of Uniti Group, Inc. following news that the Shareholder Class Action Against Uniti Group has survived the motions to dismiss in the pending securities class action and may face damages. The complaint alleges that Uniti made mate... |
Tricida to Present at the Needham Virtual Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 12:45 pm PT / 3:45 pm ET. Tricida will provide a company overview, business update and progress on the company’s key initiatives. A live webcast of the presentation will be accessible on the Tricida website at IR.Tricida.com. An archive of the webcast will be available for 90 days following the presentation. About Tricida Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Tricida is c... |
TCDA Price Returns
| 1-mo | 5.59% |
| 3-mo | -3.16% |
| 6-mo | -36.81% |
| 1-year | -80.77% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -30.35% |
| 2020 | -81.32% |
| 2019 | 60.05% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...